Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT at 2026 NEI Fall Congress
Definium Therapeutics announced the presentation of positive topline Phase 3 data for its lead candidate, DT120 ODT, at the 2026 NEI Fall Congress.
Stocks · News reference
JP Morgan Initiates Coverage On Definium Therapeutics with Overweight Rating, Announces Price Target of $84
JP Morgan initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Overweight rating and announces Price Target of $84.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Definium Therapeutics Announces Participation in Upcoming Investor Conferences
Definium Therapeutics, Inc. announced that members of its management team will participate in several upcoming investor conferences in November and December 2026.
Definium Reports Second Phase III Success in Anxiety Disorder Program
Definium Therapeutics announced positive Phase III results for DT120 ODT in generalized anxiety disorder, with the Panorama study meeting primary and key secondary endpoints. The treatment showed a 5.1-point placebo-adjusted benefit in HAM-A scores at Week 12 with rapid effects by day 2. The company plans an FDA pre-NDA meeting in Q4 2026 and NDA filing in H1 2027, with DT120 also advancing in major depressive disorder and posttraumatic stress disorder trials.
Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $78
Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $64 to $78.
Baird Maintains Outperform on Definium Therapeutics, Raises Price Target to $79
Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $75 to $79.
Definium Says Its Anxiety Drug Showed 'Unprecedented Efficacy'
Definium Therapeutics announced positive Phase 3 Panorama trial results for DT120 in generalized anxiety disorder patients.